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New generation DES are effectively used in all spectrum of coronary artery diseases (CAD)
and are replacing earlier DES and BMS. Biolimus A9-eluting stent is a new generation DES
containing the anti-proliferative drug biolimus A9 incorporating a biodegradable ablu-
minal coating that leaves a polymer-free stent after drug release enhancing strut coverage
while preventing neointimal hyperplasia. A retrospective data analysis was done in pa-
tients treated with DES, with a major share of Biolimus A9 (BA9) drug-eluting stents
(DES) at Bombay Hospital, Mumbai. A total of 158 patients with 219 lesions were treated
with DES, comprising Biolimus A9-eluting stent and others and the major adverse cardiac
events (MACE) rate and stent thrombosis (ST) at 1, 6, 12 months and 24 months were
analyzed. Mace rate was 3.16 % for average follow-up of 19 months. There were 3 cases of
ST (2 of acute and 1 of subacute onset) and one non-cardiac death reported during this
time. This retrospective data demonstrates good one- and two-year clinical safety and
efficacy of DES, especially of BioMatrix stents in real world setting.
Copyright ª 2013, Cardiological Society of India. All rights reserved.1. Introduction improved efficacy. Biodegradable polymers and polymer-freeEven though the clinical efficacy and safety in terms lower
adverse event rates and target lesion revascularization of
second generation polymer-based drug-eluting stents (DES)
such as Everolimus [(EES), Xience] and Zotarolimus [(ZES),
Endeavor] over bare-metal stents (BMS) has been shown,1e4 a
lot of focus is still on development of newer generations of
DES. This is because DESs still have late-stage disadvantages
that might be attributable to the polymer. The newer gener-
ation DES platforms aim to address concerns of safety andndia.com (H. Rangnekar)
2013, Cardiological Sociedrug delivery have shown to minimize vascular injury and
delayed stent endothelialization. Newer generation DES with
biodegradable polymers provide controlled drug release with
subsequent degradation of the polymer rendering the stent
surface more closely to a BMS after the period of biodegra-
dation. The efficacy of biodegradable polymer coated DES has
been shown to have non-inferior performance in terms of
clinical and angiographic outcomes.5e7 Couple of other ran-
domized trials have also supported these established
results.8,9.
ty of India. All rights reserved.
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(ST), especially the limus derivatives delivered from a durable
polymer platform as compared to paclitaxel in several clinical
trials.10e14 Interest in biodegradable polymer technology had
emerged as a result of concerns over very late ST that is
believed to result from the vascular inflammation and
consequential delayed endothelialization associated with the
polymers used in DES designs. DES involving biodegradable
polymers offer early benefits of reducing neointimal prolifer-
ation while reducing the risk of very late ST.
BioMatrix stents have a stainless steel stent platform that
is combined with the anti-proliferative drug Biolimus A9, a
lipophilic sirolimus analog that is bound to the stent platform
via a poly-lactic acid, a biodegradable polymer that bio-
degrades within 6e9 months. The BioMatrix stent design was
compared with the Cypher SES with permanent polymer in
the randomized, all-comers LEADERS trial and was shown to
be non-inferior for MACE (composite of cardiac death,
myocardial infarction, and ischemia-driven revasculariza-
tion) and 80% relative risk reduction of very late stent
thrombosis (1e4 years).15,16 Biolimus eluting stents have also
demonstrated good safety and efficacy profile in other ran-
domized trials.17,18 The market approval of various DESs was
based on data generated from various clinical trials5,15e17
which included low- to moderate-risk patients but majority
of patients treated in routine clinical practice fall outside the
approved indications of DES. A couple of post marketing reg-
istry studies involving DESs are also being done, which will
further add to extrapolate the clinical outcomes and long term
safety of these devices in real world setting.
Newer generation DESs are also being used in clinical
practice if available by cardiologist to treat patients with
STEMI undergoing Percutaneous Coronary Intervention (PCI).
This report includes the safety and clinical outcomes of pa-
tients in terms of MACE rate and ST for a period of around 2
years who received DES with a major share of Biolimus
A9-eluting stents during PCI at Bombay Hospital, Mumbai.Table 1 e Baseline characteristics.
Baseline characteristics N (%)
Age group (years)
20e39 11 (8.14)
40e59 69 (51.11)
60e79 50 (37.03)
80 05 (3.7)
Gender
Female 18 (11.4)
Male 140 (88.6)2. Methodology
This is a retrospective analysis of data from patients who
underwent angioplasty at Bombay Hospital, Mumbai in India
between January 2009 and March 2012. The primary objective
of this analysis was to determine device oriented major
adverse cardiac events (MACE) defined as composite of cardiac
death, myocardial infarction [MI], or target vessel revascu-
larization [TVR], and stent thrombosis (ST).
The criteria for inclusion of data for analysis were patients
who had undergone PCI with lesions suitable for stent im-
plantation with Biolimus A9-eluting stent and/or other DES
and presence of 1 coronary artery stenoses in a native cor-
onary artery and saphenous bypass graft or radial vein graft
that can be covered with one or multiple stents with no lim-
itation to the number of treated lesions, number of treated
vessels or lesion length.
Implantation of DES in each target lesion during the index
procedure was done as per the standard procedure. All post-
operative medical management, including dual antiplatelet
therapy, was prescribed according to usual local practice atthe discretion of the cardiologist. The available data collected
as part of standard medical care including demographic in-
formation, lesion and stent characteristics, and on events, if
any, were analyzed. The follow up data of the patients were
recorded as and when patients attended the clinic and was
considered for analysis. Review and analysis of all MACE and
ST were done from available hospital records including elec-
trocardiograms, and angiograms, when necessary.
All statistical analyses were performed with SPSS (Version
16.0). Standard descriptive statistics were used for baseline,
lesion, and procedural characteristics and for clinical results
for all patients. Continuous variables were presented as
mean  SD and range, and categorical variables were pre-
sented as numbers and percentages. Descriptive data of the
patient population and serious adverse events were compiled
as per protocol specified time intervals.3. Overall results
The study population included a total of 158 consecutive pa-
tients at Bombay Hospital, Mumbai who underwent single or
multi-vessel revascularization between January 2009 and
March 2012 with 219 lesions treated with Biolimus A9-
eluting stents and other DES. Patients’ baseline de-
mographics are summarized in Table 1 and Fig. 1. Lesion
characteristics and lesion stent characteristics are shown in
Tables 2 and 3, respectively. The mean age was 57.57  12
years. A total of 242 biolimus eluting stents were implanted
during the index procedure. In more than half of the patients,
63.3% had lesions that were 2.75 mm in diameter and 39.9%
patients had long length lesions (stent length ranged between
8 and 28mm). Almost three fourths of the patients (74.5%) had
single vessel disease and most of the lesions were located in
the left anterior descending artery (75.31%). On average, 1.53
stents were used to treat 1.38 lesions per patient. Hybrid
stenting (additional stent implantation other than Biolimus
A9-eluting stent) was done in a total of 23 patients.
This analysis includes average clinical follow up of 1 year
and 7 months (588 days) in 158 patients. The cumulative rates
of adverse clinical events and overall ST classification are
presented in Table 4. MACE rate was 3.16 if calculated for
average followup of 1 year and 7months. Therewere 3 cardiac
deaths and 2 cases of TVR reported. Of 3 patients who devel-
oped ST, two presented with acute onset and one with sub-
acute onset. All the patients who had stent thrombosis were
having elevated creatinine value and eGFR less than 30. There
was only one case of non-cardiac death reported.
Fig. 1 e Age group wise comparison.
Table 3 e Characteristics of lesion stent in 158 subjects.
Parameters N (%)
Total no. of lesion segments 219
Lesions per patient 1.38
Total no. of stents used 242
No. of stents used per patient 1.53
Long lesion stent length (28 mm) 63 (39.87)
Small vessel (2.75 mm) 100 (63.29)
i n d i a n h e a r t j o u r n a l 6 5 ( 2 0 1 3 ) 6 7 8e6 8 26804. Discussion
The safety and efficacy of BioMatrix been established in
several large randomized controlled trials including LEADERS
trial.8 Biolimus eluting stents also performed well in unse-
lected patient registry trial19 and randomized BES trial
compared to PES.11
The Biolimus A9-eluting stent system has shown good
results in terms of low rates of MACE (cardiac death, TVR and
MI) in this retrospective analysis. The results may be consid-
ered as significant attesting favorable clinical outcome of
Biolimus A9-eluting stents in real world setting. In this
analysis, considering small sample size of patients who
received BES stents, MACE rate (Cardiac death, MI, TVR) (3.16 if
calculated for average follow up of 1 year and 7 months.) and
ST were significantly lower. There were only 3 reported cases
of ST and there was not a single case of late onset ST.
These results are comparable to the recent real world registry
trials20e22 of newer generation DESs. This 2-year clinical
outcome data which showed apparent clinical benefit was
primarily attributable to reduced risk of very late definite ST
and this is quite supportive of an indication of long term
benefit of BA9-eluting stent. The findings from this analysis
thus supports favorable outcome from randomized and post
marketing registry trials of BioMatrix stent involving patients
with STEMI undergoing PCI in real world setting.Table 4 e Cumulative rates of adverse clinical events up
to 1 year.5. Market challenges
The introduction of drug-eluting stent (DES) technology with
significant reductions in the rates of target lesion revascu-
larization (TLR) andmajor adverse cardiac events (MACE) hasTable 2 e Characteristics of lesions treated in 158
subjects.
Lesion characteristics
Single Vessel Disease (SVD) 117 (74.5)
Multi Vessel Disease (MVD) 36 (22.78)
Triple Vessel Disease (TVD) 05 (3.16)
Lesion segments
Total no. of lesion segment N (219) (%)
RCA 42 (26.58)
LAD 119 (75.31)
LCX 51 (32.27)
Left main 05 (3.16)
Ramus 02 (1.27)dramatically altered the landscape of coronary artery disease
(CAD) revascularization. Innovation is occurring rapidly in
the coronary stents industry with technology advancing at a
fast pace. The prevalence of CAD and associated co-morbid
conditions such as hypertension, diabetes and obesity is
likely to increase and stimulate the demand for coronary
stents. Despite the progress achieved with the first-
generation DES, Cypher and Taxus, rates of MACE at 5
years remain high.23 Hence, newer generation DES such as
stents with biodegradable polymers, are projected to in-
crease the use of stents in interventional cardiology as the
current data suggests that biodegradable polymer stents
have the potential to reduce the safety concerns of durable
polymer stents. Drug, Biolimus A9 is ten times lipophilic than
its analogs, the property that ensures very much targeted
action of it. Apart from having biodegradable polymer, Bio-
Matrix stent has a coating on the outer surface (abluminal)
thereby reducing systemic exposure of drug and risk of stent
thrombosis to a great extent.6. Limitations
The results from this analysis reflect aminority of the patients
treated at only one hospital with Biolimus A9-eluting and
other stents. Secondly, the analysis was single-arm with no
control arm for direct comparison. Also, this being a retro-
spective analysis, a few variables might have been missed for
analysis.MACE (major adverse
cardiac event)
N Total MACE Rate
Cardiac death 3 5 3.16
Myocardial infarction 0
TVR 2
Stent thrombosis Acute Sub-acute Late Very late
Definite 2 0 0
Probable 0 1 0 0
Possible 0 0 0 0
*Major Adverse Cardiac Events (MACE) within the study population,
defined as composite of cardiac death, myocardial infarction (Q-
wave and non-Q-wave), or justified target vessel revascularization
at 12 months.
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In conclusion, MACE rate and ST in this small cohort of gen-
eral patients treated with Biolimus A9-eluting stents were
comparable to previously published data of clinical trials as
well as post marketing surveillance registry studies. This
retrospective data demonstrates that Biolimus A9 DES, Bio-
Matrix has a favorable clinical outcome compared to any other
DES available in the market.8. Recommendation
Trial like LEADERS has shown that a combination of Biode-
gradable polymer PLA, highly lipophilic Biolimus A9 drug
and its abluminal coating over a Juno platform is safe and
effective as compared to a permanent polymer limus eluting
stent. Our experience in Bombay Hospital confirms this. We
strongly recommend BioMatrix and BioMatrix Flex Biolimus
A9-eluting stent in the treatment of CAD. This new genera-
tion stent not only treats de novo lesions but is helping com-
plex patients and is effective in the management of STEMI
also.Conflicts of interest
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